Results 21 to 30 of about 137,029 (384)

Immunogenicity of infliximab and adalimumab [PDF]

Expert Opinion on Drug Safety, 2019
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated dise...
Murdaca G., Negrini S., Greco M., Schiavi C., Giusti F., Borro M., Puppo F.   +6 more
openaire   +5 more sources

Switch from Infliximab to Infliximab-dyyb for Rheumatology Indications [PDF]

Journal of Contemporary Pharmacy Practice, 2021
Introduction Multiple expert panels at Kaiser Permanente approved infliximab-dyyb (Inflectra®), a biosimilar to the reference product infliximab (Remicade®), to be the preferred infliximab agent for therapeutic substitution from infliximab for adult patients with dermatologic, rheumatologic, and/or gastroenterologic diagnoses.
Katie Pitcher, Rita Hui, Aeris Lautchang, Alexi Spoto   +3 more
openaire   +3 more sources

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Current Oncology, 2021
Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage.
Daniel V. Araujo, Thiago Pimentel Muniz, Anjie Yang, Sareh Keshavarzi, Hadas Sorotsky, Marcus O. Butler, Samuel Saibil, Anna Spreafico, David Hogg   +8 more
doaj   +1 more source

Infliximab for induction and maintenance therapy for ulcerative colitis.

New England Journal of Medicine, 2005
BACKGROUND Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS Two randomized, double-blind, placebo-controlled studies--the Active
P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. Hanauer, G. Lichtenstein, W. D. de Villiers, D. Present, B. Sands, J. Colombel   +13 more
semanticscholar   +1 more source

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BMC Musculoskeletal Disorders, 2011
Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and ...
van Riel Piet LCM, Hekster Yechiel A, Wolbink GJ, den Broeder Alfons A, van den Bemt Bart JF, Benraad Bart, van den Hoogen Frank HJ   +6 more
doaj   +1 more source

Safety aspects of infliximab in inflammatory bowel disease patients - A retrospective cohort study in 100 patients of a German University Hospital [PDF]

, 2004
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD).
Ali Y, Baker D, Burkhard Göke, Cohen RD, Hanauer S, Hommes DW, Jani AL, Julia Seiderer, Puchner TC, Sample C, Sandborn WJ, Thomas Ochsenkühn   +11 more
core   +1 more source

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

BMC Musculoskeletal Disorders, 2012
Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Methods In a ...
van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A   +5 more
doaj   +1 more source

Infliximab, azathioprine, or combination therapy for Crohn's disease.

New England Journal of Medicine, 2010
BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy ...
J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth, D. Rachmilewitz, S. Lichtiger, G. D'Haens, R. Diamond, D. Broussard, K. Tang, C. J. van der Woude, P. Rutgeerts   +12 more
semanticscholar   +1 more source

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]

, 2009
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core   +1 more source

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

New England Journal of Medicine, 2000
BACKGROUND Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are ...
eter, L. E., Ipsky, Esiree, M. M.F., Van Der, Eijde, Aniel, F. E., Urst, Erdinand, B. C, Reedveld, Oachim, K. R., Alden, Osef, S. S., Molen, Ichael, Eisman, Aul, Mery, regory, H. R., Arriman, Avinder, M. N., Aini   +28 more
semanticscholar   +1 more source